July 16, 2020
NIH, Moderna’s COVID-19 vaccine headed to Phase III trial
Editor's Note
Researchers testing a COVID-19 vaccine being developed by Dr Anthony Fauci’s team at the National Institutes of Health (NIH) and Moderna Inc, reported July 14 that the vaccine was able to produce neutralizing antibodies in the 45 trial participants inoculated in March.
Moderna is scheduled to launch a late-stage trial to evaluate the vaccine in 30,000 volunteers at the end of July.
Free Daily News
- Infusion pumps deemed high-risk in FDA early alert
- Stem cell researchers tout potential for sickle cell disease cure
- Study: Stem cell therapy restores vision in LSCD patients
- AMSURG launches nationwide campaign to spotlight rising colon cancer rates, urges early screening
- AAAHC seeks stakeholder feedback on revised v44 standards to elevate patient-centered care
- Hospital’s anesthesia reforms slash carbon footprint, expenses
- Study: Shifting imaging to outpatient centers could save billions
- Report: Health system margins shrink as hospital revenue grows
- Study: Cataract surgery increases diabetic retinopathy progression
- FDA announces Class 1 endovascular system, anesthesia system recalls
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement